JP2007506442A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506442A5
JP2007506442A5 JP2006533538A JP2006533538A JP2007506442A5 JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5 JP 2006533538 A JP2006533538 A JP 2006533538A JP 2006533538 A JP2006533538 A JP 2006533538A JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5
Authority
JP
Japan
Prior art keywords
expression
array
cancer
ckap4
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/017215 external-priority patent/WO2004111273A2/en
Publication of JP2007506442A publication Critical patent/JP2007506442A/ja
Publication of JP2007506442A5 publication Critical patent/JP2007506442A5/ja
Pending legal-status Critical Current

Links

JP2006533538A 2003-05-30 2004-05-28 Egfr阻害薬への応答に関する遺伝子発現マーカー Pending JP2007506442A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47490803P 2003-05-30 2003-05-30
PCT/US2004/017215 WO2004111273A2 (en) 2003-05-30 2004-05-28 Gene expression markers for response to egfr inhibitor drugs

Publications (2)

Publication Number Publication Date
JP2007506442A JP2007506442A (ja) 2007-03-22
JP2007506442A5 true JP2007506442A5 (enExample) 2007-07-05

Family

ID=33551513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533538A Pending JP2007506442A (ja) 2003-05-30 2004-05-28 Egfr阻害薬への応答に関する遺伝子発現マーカー

Country Status (6)

Country Link
US (2) US20050164218A1 (enExample)
EP (2) EP2226396A1 (enExample)
JP (1) JP2007506442A (enExample)
AU (2) AU2004248140A1 (enExample)
CA (1) CA2527321A1 (enExample)
WO (1) WO2004111273A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059012A1 (en) * 2002-07-31 2005-03-17 Daniel Afar Diagnosis of ZD1839 resistant tumors
US20050267689A1 (en) * 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc OXYGEN-IMPROVED MEMBRANE SYSTEMS FOR IMPLANTABLE DEVICES
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005117553A2 (en) * 2004-05-27 2005-12-15 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
ES2564127T5 (es) 2004-06-04 2020-03-26 Genentech Inc Mutaciones en EGFR
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1861715B1 (en) 2005-03-16 2010-08-11 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7635570B2 (en) 2005-04-01 2009-12-22 Salvatore Siena Epidermal growth factor receptor gene copy number
EP1871911A2 (en) * 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
CN101155932A (zh) * 2005-04-14 2008-04-02 默克专利有限公司 基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗
EP2460886B1 (en) * 2005-05-04 2014-01-01 University of South Florida Predicting treatment response in cancer subjects
JP2008546421A (ja) * 2005-06-28 2008-12-25 ジェネンテック・インコーポレーテッド Egfrおよびkras変異
JP5055284B2 (ja) * 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
DE602007009645D1 (de) * 2006-02-16 2010-11-18 Ventana Med Syst Inc Reagenzien und verfahren für krebsprognose und pathologische einstufung
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
JP2007252312A (ja) * 2006-03-24 2007-10-04 Japan Health Science Foundation 上皮成長因子受容体−チロシンキナーゼ阻害剤に対する肺ガンの感度測定方法および肺ガン治療剤のスクリーニング方法
US7858389B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US8024282B2 (en) * 2006-03-31 2011-09-20 Biodesix, Inc. Method for reliable classification of samples in clinical diagnostics using an improved method of classification
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
CN101449162B (zh) 2006-05-18 2013-07-31 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20070281305A1 (en) * 2006-06-05 2007-12-06 Sean Wuxiong Cao Detection of lymph node metastasis from gastric carcinoma
JP2010503407A (ja) * 2006-09-12 2010-02-04 ジェネンテック・インコーポレーテッド 癌の診断及び治療のための方法及び組成物
RS56422B1 (sr) 2007-03-13 2018-01-31 Amgen Inc K-ras mutacije i terapija anti-egfr antitelom
WO2008127719A1 (en) 2007-04-13 2008-10-23 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to kinase inhibitors
WO2009023172A2 (en) * 2007-08-09 2009-02-19 The Johns Hopkins University Predictions of responsiveness to egfr inhibitors
EP2179056B1 (en) * 2007-08-14 2012-09-19 F. Hoffmann-La Roche AG Egfr inhibitor treatment marker
US20110212979A1 (en) * 2007-08-14 2011-09-01 Paul Delmar Predictive marker for egfr inhibitor treatment
WO2009021679A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treamtent
AU2008286408A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for EGFR inhibitor treatment
WO2009021683A2 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Predictive marker for egfr inhibitor treatment
MX2010001583A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
WO2009045389A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045361A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2288727B1 (en) * 2008-05-14 2013-07-10 Genomic Health, Inc. Predictors of patient response to treatment with egf receptor inhibitors
WO2010015535A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2010015538A2 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2010015536A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
CN106153918A (zh) * 2008-10-14 2016-11-23 卡里斯Mpi公司 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
CA2741906A1 (en) * 2008-10-29 2010-05-14 William Beaumont Hospital Methods of using biomarkers
EP2730662A1 (en) 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
JPWO2010064702A1 (ja) * 2008-12-05 2012-05-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー
WO2010099137A2 (en) * 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
CN102770760A (zh) * 2010-02-24 2012-11-07 佰欧迪塞克斯公司 利用质谱分析选择施用治疗剂的癌症患者
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
JP2013527748A (ja) 2010-03-03 2013-07-04 オーエスアイ・ファーマシューティカルズ,エルエルシー インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
AU2012209515B2 (en) 2011-01-28 2015-07-23 Biodesix, Inc. Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
KR20140057356A (ko) 2011-08-31 2014-05-12 제넨테크, 인크. 진단 마커
WO2013055530A1 (en) 2011-09-30 2013-04-18 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
AU2013224591A1 (en) * 2012-02-22 2014-07-24 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CN103408662A (zh) * 2013-08-15 2013-11-27 浙江农林大学 一种抗蟾皮转胶蛋白-2重组蛋白的鼠抗血清的制备方法
WO2015178946A1 (en) 2014-04-04 2015-11-26 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
ES2750832T3 (es) * 2014-07-29 2020-03-27 Wellmarker Bio Co Ltd Nuevo biomarcador para predecir la sensibilidad al agente dirigido contra egfr y uso del mismo
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
KR102406696B1 (ko) * 2020-06-19 2022-06-08 (주)신테카바이오 약물 민감도 판단을 위한 유전자 검출 방법 및 진단용 조성물
WO2022255401A1 (ja) * 2021-06-03 2022-12-08 国立大学法人 東京大学 Erk-mapk経路の異常な活性化に伴い発現する疾患マーカー

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
DK0868519T3 (da) * 1995-12-18 2006-05-08 Sugen Inc Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
IL130036A (en) * 1996-11-20 2010-04-15 Univ Yale Sarbivine polypeptides, nucleic acids encode the polypeptides and their utilization
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
US9534254B1 (en) * 1999-02-02 2017-01-03 Abbott Molecular Inc. Patient stratification for cancer therapy based on genomic DNA microarray analysis
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051661A2 (en) * 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) * 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
WO2001075159A2 (en) * 2000-03-31 2001-10-11 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
JP2004509612A (ja) * 2000-06-05 2004-04-02 アバロン ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
IL154037A0 (en) * 2000-07-21 2003-07-31 Global Genomics Ab Methods for analysis and identification of transcribed genes, and fingerprinting
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
WO2002057787A2 (en) * 2001-01-12 2002-07-25 Yale University Detection of survivin in the biological fluids of cancer patients
US20030199685A1 (en) * 2001-03-12 2003-10-23 Monogen, Inc. Cell-based detection and differentiation of disease states
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
WO2003039443A2 (en) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
CA2466502A1 (en) * 2001-11-09 2003-05-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP1570080A4 (en) * 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE

Similar Documents

Publication Publication Date Title
JP2007506442A5 (enExample)
US8198024B2 (en) Gene expression markers for colorectal cancer prognosis
ES2821300T3 (es) Predicción de pronóstico para el melanoma de cáncer
US20120028264A1 (en) Method for using gene expression to determine prognosis of prostate cancer
JP2014509189A (ja) 結腸ガン遺伝子発現シグネチャーおよび使用方法
JP7665659B2 (ja) 循環腫瘍核酸分子のマルチモーダル分析
CN103403187A (zh) 结肠直肠癌复发的预后特征
CN105431738A (zh) 胃癌的预后预测模型的建立方法
KR20180002882A (ko) 유전자 발현 프로파일 및 유방암에 대한 이의 용도
EP2780476B1 (en) Methods for diagnosis and/or prognosis of gynecological cancer
KR20170072685A (ko) 삼중음성유방암의 아형 분류 방법
MX2011006926A (es) Metodos y medios para categorizar una muestra que comprende celulas de cancer colorrectal.
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
Somura et al. A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy
Tsao et al. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients
EP4486917A2 (en) Methylated dna markers and assays thereof for use in detecting colorectal cancer
JP2024519082A (ja) 肝細胞がんのdnaメチル化バイオマーカー
CN117265104A (zh) LncRNA生物标志物在结直肠癌诊疗中的应用
CN113957145A (zh) m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN110846417A (zh) 头颈部鳞癌诊治标志物
HK40092784A (zh) 循环肿瘤核酸分子的多模态分析
WO2024192053A1 (en) Methods of developing cancer diagnostic models and uses thereof in developing cancer detection methods
EP4680743A1 (en) Methods of developing cancer diagnostic models and uses thereof in developing cancer detection methods
HK40126608A (zh) 开发癌症诊断模型的方法及其在开发癌症检测方法中的用途
CN104039980A (zh) 精子蛋白作为早期卵巢癌的检测生物标记物